19.08.2016 • News

Frutarom Enters Irish Market with Redbrook Buy

Flavors and fine ingredients company Frutarom has agreed to buy Ireland’s Redbrook Ingredients Services for around $44.8 million. The purchase price also includes provision for an additional payment based on future performance. Redbrook’s principal market is specialty savory flavors. The company has an R&D, sales and marketing center and a production site near Dublin, as well as in Daventry, UK, near to Frutarom’s premises in Wellingborough. It posted sales of roughly $25.4 million for the year ending June 2016.

The acquisition, which is said to be largely synergistic with Frutarom’s activities, strengthens the Israeli firm’s leading position in the UK and marks its first entry into the Irish market. Frutarom’s president and CEO Ori Yehudai said the deal generated many cross-selling possibilities as well as opportunities to expand its customer base and product portfolio.

Redbrook’s CEO Kieran Fox will continue in his role and join Frutarom’s management. Frutarom has been building up its activities during the past 10 years in the savory flavors market. It said rising living standards and changes in lifestyles were boosting demand worldwide for savory taste solutions, both in home consumption and dining out.

Yehudai added that Frutarom had a strong pipeline of potential strategic acquisitions as it continued to focus on expanding into high-growth markets. The company has set itself a target of achieving sales of at least $2 billion with an EBITDA margin of more than 22% in its core activities by 2020.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read